Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 58

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 58
---
 we regard as our own. Our and their assignment agreements may not be self-executing
or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’
or collaborators’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors
or collaborators fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights, such as exclusive ownership of, or right to use, intellectual property that is important to our drug candidates. Even if we are
successful in defending against such claims, these claims may create considerable distraction to management and other employees of the
company. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection, if any, afforded
by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect
our business or permit us to maintain our competitive advantage. For example:

| · | others may be able to make products that are similar to any drug candidates we may develop or utilize              
 similar technology but that are not covered by the claims of the patents that we license or may own in the future; |

| · | we, or our current or future licensors or collaborators, might not have been the first to make the inventions 
 covered by the issued patent or pending patent application that we license or may own in the future;          |

| · | we, or our current or future licensors or collaborators might not have been the first to file patent applications 
 covering certain of our or their invention;                                                                       |

| · | others may independently develop similar or alternative technologies or duplicate any of our technologies 
 without infringing our owned or licensed intellectual property rights;                                    |

| · | it is possible that our pending owned or licensed patent applications or those that we may own or license 
 in the future will not lead to issued patents;                                                            |

| · | issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal 
 challenges by our competitors;                                                                             |

| · | our competitors might conduct research and development activities in countries where we do not have patent                                 
 rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; |

<div align='center'>27</div>

| · | we may not develop additional